Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. Vertex's gene-editing therapy for sickle cell ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

Prof Bola Owolabi, of NHS England, called it a "monumental step forward", and said the one-off treatment Casgevy, also known as Exa-cel, "holds a very real prospect of a cure". A confidential ...

The monthslong treatment Casgevy from Vertex Pharmaceuticals comes with a list price of $2.3 million. Bluebird Bio’s Lyfgenia is listed at $3.1 million. Neither includes the cost of care to stay ...

The deal is notable because the U.K.’s cost-effectiveness watchdog initially raised concerns about the durability of the treatment, called Casgevy, in a preliminary ruling last year, saying it ...

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...

Its first treatment, Casgevy, earned approval from the Food and Drug Administration (FDA) to treat sickle cell disease in December 2023. Last January, the FDA approved Casgevy again to treat ...

“Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across oncology, autoimmune and cardiometabolic indications. 2025 promises to be a milestone-rich ...